High dose oral rifampicin to improve survival from adult tuberculous meningitis: A randomised placebo-controlled double-blinded phase III trial (the HARVEST study)

Background: Tuberculous meningitis (TBM), the most severe form of tuberculosis (TB), results in death or neurological disability in >50%, despite World Health Organisation recommended therapy. Current TBM regimen dosages are based on data from pulmonary TB alone. Evidence from recent phase II pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Marais, Suzaan, Cresswell, Fiona V, Hamers, Raph L., te Brake, Lindsey H.M., Ganiem, Ahmad R., Imran, Darma, Bangdiwala, Ananta, Martyn, Emily, Kasibante, John, Kagimu, Enock, Musubire, Abdu, Maharani, Kartika, Estiasari, Riwanti, Kusumaningrum, Ardiana, Kusumadjayanti, Nadytia, Yunivita, Vycke, Naidoo, Kogieleum, Lessells, Richard, Moosa, Yunus, Svensson, Elin M., Huppler Hullsiek, Katherine, Aarnoutse, Rob E., Boulware, David R., van Crevel, Reinout, Ruslami, Rovina, Meya, David B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542255/
https://www.ncbi.nlm.nih.gov/pubmed/33083560
http://dx.doi.org/10.12688/wellcomeopenres.15565.2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542255/
https://www.ncbi.nlm.nih.gov/pubmed/33083560
http://dx.doi.org/10.12688/wellcomeopenres.15565.2

Ejemplares similares